British National Formulary November 2024 Update
This update contains 10 significant changes, 4 dose changes, 5 new monographs, and 5 new preparations.
Significant Changes:
- Antibacterials, principles of therapy: update to notifiable diseases reporting.
- Antibacterials, use for prophylaxis: updated guidance on secondary prevention of meningococcal disease and secondary prevention of pertussis.
- Borderline substances: oral nutritional supplements have been re-organised in a new section called Oral nutrition.
- Co-amoxiclav: update to structure of indications and dose section; tablet dose expression changed to co-amoxiclav (total of amoxicillin and clavulanic acid).
- Faricimab: new indication and dose for macular oedema secondary to retinal vein occlusion.
- Immunisation schedule: updated guidance for immunisation against influenza, and for pertussis in pregnancy.
- Lower urinary tract symptoms in males: new guidance.
- Oxytocin: risk of overdose during labour and childbirth [NPSA advice].
- Pertussis vaccine: updated guidance for immunisation.
- Topical corticosteroids: update to the list of topical corticosteroid potencies.
Dose Changes:
- Ciprofloxacin [indication changed from prevention of secondary case of meningococcal meningitis to prevention of secondary case of meningococcal disease].
- Lithium carbonate [update to dosing].
- Lithium citrate [update to dosing].
- Risankizumab [update to dosing].
New Monographs:
- Fabhalta® [iptacopan].
- Isoprenaline hydrochloride.
- Mepsevii® [vestronidase alfa].
- Obgemsa® [vibegron].
- Yselty® [linzagolix].
New Preparations: Ceyxa® [olanzapine]; Co-amoxiclav 1 g (875/125 mg) tablet; Co-amoxiclav 2.2 g (2000/200 mg) infusion; Metalyse® 5000 units (25 mg) [tenecteplase]; Xyquila® [olanzapine].